SANA: The Most Asymmetric Biotech Opportunity Nobody Is WatchingSana Biotechnology, Inc.BATS:SANAKingsii13Update on SANA, The local accumulation model isn't showing the strength I wanted to see. I now expect another reaccumulation phase before the larger expansion. But here's what makes SANA particularly interesting. THREE separate macro accumulation models at macro lows. Three. At some point, you have to start asking yourself what is happening beneath the surface. Within my framework, this is exactly the type of structure I associate with heavy institutional scaling and market-maker positioning. And biotech is where things get particularly interesting. Pre-commercial biotech valuations are heavily influenced by clinical trial outcomes, regulatory milestones, and institutional capital. Information asymmetry can be enormous. Making it very easy for insiders to position themselves before the Public announcements are made. SANA's clinical pipeline remains the fundamental catalyst, with important development milestones extending into 2027. That longer timeline also creates room for the market to build another accumulation structure before the next major release. The local model lacks strength. The macro structure tells a different story. Three accumulation models at macro lows make it very obvious that there are institutions/insiders positioning themselves for years now. These Models do not happen without a reason behind it. People like to believe markets are perfectly fair and every participant operates with the same information. I don't trade under that assumption. My edge is looking for the footprints of larger participants before the crowd recognizes the opportunity. If another reaccumulation confirms, SANA could become one of the most assymetric macro biotech setups I've mapped. The game isn't played on equal terms. You just have to become good enough at reading the board.